NurExone Biologic FY26 Q2 net loss narrows 2.13% to US$ 3.45 million

Reuters2026/08/31 14:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NurExone posted a six-month net loss of US$ 3.45 million, narrowing 2.13% from the prior-year period; loss per share improved to US$ 0.04.
Operating loss narrowed to US$ 3.43 million from the prior-year period, as R&D climbed 4.79% to US$ 1.38 million.
General and administrative costs fell 6.93% to US$ 2.05 million; cash and cash equivalents dropped to US$ 1.01 million.
Net cash used in operating activities increased to US$ 2.19 million from the prior-year period; private placements contributed US$ 1.06 million.
Exo-Top signed an MOU with ExoLyra for exclusive Mexico distribution, including a US$ 180,000 territorial exclusivity fee and annual minimum purchases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief on August 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NurExone Biologic FY26 Q2 net loss narrows 2.13% to US$ 3.45 million

You may also like

Crypto prices